Nusano, Inc. and PharmaLogic have joined forces to revolutionize the production of cancer-fighting radioisotopes, creating innovative radiopharmaceuticals for diagnostic and therapeutic purposes. As a world-class CDMO, PharmaLogic brings to the table a wealth of expertise and experience in radiopharmaceuticals. Together, the two companies are set to revolutionize the field and make life-saving treatments more accessible to those in need.
Chris Lowe, CEO of Nusano, is thrilled to be partnering with PharmaLogic to revolutionize cancer care. By combining forces and leveraging the close proximity of our facilities in the greater Salt Lake area, we are creating the perfect environment to develop the next generation of radiopharmaceuticals and provide our customers with the best outcomes possible. Together, we are paving the way to a brighter future for cancer patients.
As the world enters the first quarter of 2025, Nusano is set to revolutionize the medical industry with the opening of its breakthrough facility in West Valley City, Utah. This facility will provide an unprecedented level of medical isotope production, allowing for larger quantities and multiple isotopes to be generated simultaneously. This will be a major step forward in providing better patient care and accelerating therapeutic development.
PharmaLogic is coming to Salt Lake City! The organization’s expansion of its CDMO and radiopharmaceutical manufacturing capabilities into the Mountain West region of the United States will be completed by the end of 2023. This new facility is just one of the many steps PharmaLogic has taken towards increasing access to the latest radiopharmaceutical technology for patients across the country.
In addition to their established radiopharmacy business, PharmaLogic has been investing in its cyclotron network to provide the best possible care. Don’t miss out on this exciting opportunity to benefit from their cutting-edge technology!
Scott Holbrook, Chief Strategy Officer and General Manager for PharmaLogic, is excited about the potential of Nusano’s new facility to help ensure a stable supply chain of radioisotopes for critical diagnostics and treatments.
“Radioisotope supply chain stability is critical to get these life-saving treatments to patients when they are needed,” he said. “With Nusano’s facility coming online, we can take an important step towards providing quality and predictability for our customers. We look forward to working together to accelerate new and emerging cancer diagnostics and treatments.”
About Nusano, Inc.
Nusano is revolutionizing the medical radioisotopes market with their innovative, cutting-edge ion source. This revolutionary technology allows for greater yields and the ability to manufacture multiple radioisotopes simultaneously.
Nusano’s technology will support the fight against cancer, as well as offer diagnostic and therapeutic radiopharmaceutical development. The company is set to open their state-of-the-art production facility in West Valley City, Utah in Q1 2025, bringing stability and innovation to the medical radioisotopes market.